MP48-08 RESPONSE RATES AND SURVIVAL OUTCOMES OF METASTASIS DIRECTED THERAPIES IN SOLITARY OLIGO-RECURRENT PROSTATE CANCER

Abstract

You have accessJournal of UrologyCME1 May 2022MP48-08 RESPONSE RATES AND SURVIVAL OUTCOMES OF METASTASIS DIRECTED THERAPIES IN SOLITARY OLIGO-RECURRENT PROSTATE CANCER Mohamed Ahmed, Jack Andrews, Vidit Sharma, Cameron Britton, Vidhu Joshi, Bradley Stish, Ryan Phillips, R. Jeffrey Karnes, and Eugene Kwon Mohamed AhmedMohamed Ahmed More articles by this author , Jack AndrewsJack Andrews More articles by this author , Vidit SharmaVidit Sharma More articles by this author , Cameron BrittonCameron Britton More articles by this author , Vidhu JoshiVidhu Joshi More articles by this author , Bradley StishBradley Stish More articles by this author , Ryan PhillipsRyan Phillips More articles by this author , R. Jeffrey KarnesR. Jeffrey Karnes More articles by this author , and Eugene KwonEugene Kwon More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002619.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Much controversy exists regarding the role of metastasis-direct-therapy (MDT) in patients with oligometastatic prostate cancer. We sought to assess whether there is a role for MDT without ADT in oligometastatic prostate cancer by evaluating a select subset of patients who present early with a solitary metastatic lesion on PET imaging and whose primary tumor has already been treated. METHODS: We identified 124 prostate cancer patients from 2008 to 2018 with solitary oligo-recurrent metastatic lesions on PET imaging who were treated with MDT without ADT from the Mayo Clinic C-11 Choline registry. Patients were treated with either stereotactic body radiation therapy (SBRT) or surgical excision and these cohorts were analyzed separately. RESULTS: Of these 124 patients, 67 were treated with surgery (median follow-up of 54 months) and 57 patients were treated with SBRT (median follow-up of 53 months). Of patients treated with surgery, 86% had >50% decline in PSA at first follow up (Figure 1a) and a median time to radiographic progression of 15 months (Figure 2a). Of patients treated with SBRT, 51% had >50% decline in PSA at first follow up (Figure 1b) and a median time to radiographic progression of 12 months (Figure 2b). CONCLUSIONS: This study represents the first reported series of metastasis directed therapy in patients with solitary metastatic prostate cancer. These results suggest that metastasis directed therapy alone can delay progression of disease, delay initiation of systemic therapy and may have role in the treatment of oligometastatic prostate cancer. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e823 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mohamed Ahmed More articles by this author Jack Andrews More articles by this author Vidit Sharma More articles by this author Cameron Britton More articles by this author Vidhu Joshi More articles by this author Bradley Stish More articles by this author Ryan Phillips More articles by this author R. Jeffrey Karnes More articles by this author Eugene Kwon More articles by this author Expand All Advertisement PDF DownloadLoading ...